Linked Life Data

15226333

Source:http://linkedlifedata.com/resource/pubmed/id/15226333

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
13
pubmed:dateCreated
2004-6-30
pubmed:abstractText
To evaluate the safety and efficacy of liposomal doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (AIDS-NHL). Secondary objectives were to assess the impact of HIV viral control on response and survival, and to correlate MDR-1 expression with outcome.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2662-70
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
pubmed:affiliation
Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. alevine@usc.edu
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II, Clinical Trial, Phase I